Latest / The MaineHealth Podcast / WTKE: MaineHealth Precision Medicine -- Personalizing Care, Transforming Lives
Transcript
- 0:09Hello, and welcome to Working Together with Kelly Elkins. I'm your host,
- 0:12Kelly Elkins, your Chief Operating Officer for MaineHealth.
- 0:15In this podcast series, I will be joined each episode by guests who are participating
- 0:20on teams focused on how we can support and enhance how we work together across
- 0:25MaineHealth so that we can achieve our vision of working together so that our
- 0:29communities are the healthiest in America.
- 0:31In particular, we will highlight work we are doing in further development of
- 0:35our operating model for MaineHealth and how we are creating structure and processes
- 0:39that make it easier for you to do your work.
- 0:42Today's episode is titled, MaineHealth Genomics and Precision Medicine,
- 0:47Personalizing Care, Transforming Lives.
- 0:49In today's episode, we're diving into one of the most transformative efforts
- 0:54in modern medicine, Maine Health's Genomics and Precision Medicine Initiative.
- 0:59In today's episode, we'll explore the why behind the initiative,
- 1:03the partnerships fueling its growth, and the roadmap for integrating genomics
- 1:07into primary care and beyond.
- 1:09We'll also discuss what this means for our clinicians and our patients.
- 1:14To join me in the conversation today are my guests,
- 1:18Adrian Morin, MD, Chief Medical and Transformation Officer for MaineHealth,
- 1:23and Aji Djamali, MD, Vice President, Chair of the Department of Medicine for
- 1:28MaineHealth, Maine Medical Center. Welcome to the podcast!
- 1:31Thank you for having us. As we get started, Adrian, I want to start with you.
- 1:36And, you know, from a transformation lens, what near-term milestones are signaling
- 1:43that genomics and precision medicine are really becoming part of routine clinical
- 1:47care versus a pilot or some adjunct kind of clinical trial aspect?
- 1:54That's a very good question. I think it's worth acknowledging that for decades,
- 2:00genomics has been part of pediatrics.
- 2:04So babies are born, they have serious medical condition, and often there's a
- 2:11single gene abnormality that explained who they are or a chromosomal abnormality,
- 2:17which is a larger part of their genetic setup.
- 2:21And a classic example of chromosomal abnormality is a patient with Down syndrome.
- 2:26So we've known about that for decades, but we're now at an inflection point
- 2:32in the last few years where genetics has an integral part of how we care for
- 2:41adults with various different conditions.
- 2:43And I think the other thing, and I'll give you a couple of examples in a minute.
- 2:47But I think the other thing is we've always tried within medicine to tailor
- 2:53the care for the individual, putting that on the back of evidence-based medicine.
- 2:59So two examples, two fields. One is in oncology.
- 3:03Some people are born with a genetic predisposition to cancer.
- 3:08The breast cancer gene, the BRCA gene is a great example of that.
- 3:12And it's not just breast cancer. It's also ovarian pancreatic cancer.
- 3:16But others, it's the environment in which they have lived or how they've lived.
- 3:21So smokers, we know, are at increased risk of a variety of different cancers.
- 3:26That smoking created damage to their DNA.
- 3:29So we're learning more about susceptibility within families on the back of individuals.
- 3:37In the world of cardiology, we now know that between 30 and 40% of patients
- 3:44who have a weak muscle of their heart,
- 3:46not a cardiomyopathy that's due to coronary artery disease or a heart attack.
- 3:52But they come, they have an unexplained weakness in the ventricles, the pumps of the heart.
- 3:59We now can test and find out that 30 or 40% of those are because of genetic predispositions.
- 4:07And so you're now seeing cardiologists and oncologists and oncologic surgeons,
- 4:13having to become more and more comfortable with genetic insights,
- 4:18genetic information, and that translates then into the conversations they're
- 4:23having with their patients. Yeah.
- 4:25So maybe an interesting question for you.
- 4:28I'm sure still, even though it is becoming more prevalent in the conversation,
- 4:34likely for the broader community, patients,
- 4:39you know, just non-healthcare professionals, maybe even within healthcare professionals,
- 4:45there may be some misconceptions or myths or what they think genomics is or precision medicine is.
- 4:53What's kind of one myth in this space that you think would be important to bust
- 4:58for folks? There might be a lot.
- 5:01I think one that's probably the most important as it relates to you,
- 5:08me, and everybody else is, if
- 5:10you do get tested and you detect a genetic mutation or a predisposition,
- 5:17it is not a given that you will develop whatever condition. That condition.
- 5:23So there's a concept of genetic predisposition.
- 5:27In the past, I think people thought, oh, I have it. I will develop -- Right.
- 5:32It will result in X, Y, or Z. What we know is that it definitely shifts the risk of it.
- 5:41And by knowing that susceptibility, can we influence or affect change,
- 5:47whether it's on screening, maybe the way you live your life or the lifestyle
- 5:52you have, maybe we can introduce medication,
- 5:55surgery, whatever, that will modify the natural history.
- 6:00So then even though you are susceptible to this,
- 6:04we can either completely prevent it, delay it, or detect it earlier. Yeah.
- 6:09I thought you were going to say that we're not going to be cloning people because
- 6:13we have their whole genome. I could have gone there.
- 6:17You know, Dolly the sheep and stuff. Well, yeah, never say never, right?
- 6:24For now, we're not going there. There's probably some ethical overlays as well.
- 6:30So, Aji, really want to pull you into the conversation. And as we think about
- 6:36MaineHealth and where we want to head with genomics and precision medicine,
- 6:41you know, what's our North Star?
- 6:44And how does it advance our system-wide mission of being proactive,
- 6:49predictive, and really delivering that personalized care that Adrian talked
- 6:53about? Thank you, Kelly.
- 6:55There is increasing evidence, as Adrian was implying,
- 7:00that genetic testing and precision medicine at large improve the quality of
- 7:06life and actually improve life in general, life expectancy.
- 7:11So our true north for this group is that MaineHealth becomes the leader in
- 7:20northern New England for precision medicine and genetic testing in 10 years.
- 7:25To your second question, we have been working with 60-plus people since Adrian
- 7:31and Andy Mueller asked us to work on this project to develop a platform and a
- 7:37stepwise approach for our health system to get to that level in about 10 years.
- 7:42A bit more specifically, how can this really help our patients and our people
- 7:47from Maine and New Hampshire to live longer and with a better quality of life?
- 7:52One approach is early risk assessment.
- 7:55We have also preventive measures based on that early assessment that can help us.
- 8:00For example, enhanced screening, preventing medications,
- 8:05prophylactic surgery, targeted treatment for conditions that we identify,
- 8:09and finally and importantly,
- 8:13shared decision making with patients and their family members because that can
- 8:16result in cascade testing for family members that could also benefit from this approach.
- 8:23So together, I think that we can really work so that our communities are the healthiest in America.
- 8:30That's probably one of the most creative ways that I've heard the vision get
- 8:34wrapped in. Andy will be impressed by that. There you go. He will.
- 8:39Well, so to do all of that, and Adrian, you know, you gave some great examples
- 8:43of how this is playing out, particularly in some of the specialty spaces.
- 8:48But, Aji, where will our patients first experience genomics or precision medicine in their care journey?
- 8:57Is it going to be through the specialty lens?
- 9:00Does primary care play a role in this? How will this come to life for our patients?
- 9:07Thank you. Sure. So the first part of this 10-year journey is going to focus
- 9:13on our primary care patients.
- 9:17And we are anticipating inviting about 60,000 patients in the states of Maine
- 9:25and New Hampshire to participate in this pilot study.
- 9:30And the next phases will get to specialty care, and by the end of the 10 years,
- 9:39we will have a fully integrated,
- 9:42hopefully multidisciplinary precision medicine program that will include not
- 9:47only genetic testing, but also proteomics, other biomarkers to advance our mission and vision.
- 9:54So how does this work? This is probably the most exciting part of this discussion
- 9:59for me through the primary care offices is that we are going to reach out through
- 10:05MyChart to our patients at these primary care sites and invite them to participate in this study,
- 10:12explaining to them what this is about and allowing them to have conversations
- 10:18with genetic counselors,
- 10:20research coordinators, and potentially even their primary care physicians to
- 10:25have clarifications around this process.
- 10:29Then the consent will be primarily a digital consent process and our patients
- 10:35will have the ability to do that.
- 10:37As soon as the consent is taken care of, our genetic counselor and research
- 10:42coordinators will send information,
- 10:45kit to the patient at their home. And this kit is just a simple kit that will
- 10:50allow them to do a cheek swab that will be sent to NorDx, our own clinical laboratory.
- 10:58And then we will do primarily the testing either here at NorDx or through partnership
- 11:05with our colleagues at Dartmouth.
- 11:08And the results will be sent back to us.
- 11:11Once we get the results back, we will have two more boards for genomics, for example,
- 11:16and that multidisciplinary board will look at the results and inform the genetic
- 11:23counselor and the primary care physician as to how to proceed for the next steps.
- 11:27Should that patient see a cardiologist or see a gastroenterologist for a colonoscopy
- 11:33or another specialist for that specific intervention?
- 11:38And we will keep a close loop on this to monitor that we are following the right tracks.
- 11:43And that is really the first step of this pilot study. So let me ask maybe a
- 11:49more granular question.
- 11:52What will we be screening for? Is it one particular type of genetic condition? Is it multiple?
- 12:00How are we picking what we're screening for with that data? That's a great question.
- 12:06The CDC has come up with a list of 10 genes. They call them CDC Tier 1 genes.
- 12:13These are 10 genes that are commonly associated with cancer or cardiovascular
- 12:20disease, as Adrian was mentioning earlier, or high cholesterol conditions.
- 12:26In addition to these 10 genes, we have identified another list of about 80 genes
- 12:31that address mutations in the metabolism of drugs, as well as other cardiovascular
- 12:39and cancer-related genes.
- 12:41The reason we have selected these genes is that there are established interventions
- 12:46so that we can help affected patients and their families if the diagnosis is positive.
- 12:53So that is really the approach and the reason we selected those genes. Great.
- 12:59So Adrian, genomics and precision medicine is going to require investment. Sure.
- 13:05So as we think about what it's going to take to really invest and do this work,
- 13:11how are we thinking about prioritizing the investments, whether it's in.
- 13:16Clinical programs, data, infrastructure, or the team needed to deliver this?
- 13:23Do we have everything we need today to pull this off, or will we be making some
- 13:28investments in this space?
- 13:30We'll definitely need to make some investments. We do already have people who
- 13:35are knowledgeable in the area, both on the physician side, on the genetic counselor
- 13:40side, in the research arena, and also in the laboratory.
- 13:45But, you know, you have to walk first, then run. And so that gets us only so far.
- 13:53Most of those individuals and skill sets are concentrated either in pediatrics,
- 13:59cardiology, or oncology.
- 14:01But we now need to sort of broaden the lens on where we're focusing.
- 14:08And so, this pilot study that Aji was talking about will require us to start
- 14:14to recruit more genetic counselors,
- 14:17make them available using virtual perspectives so that we can then service or
- 14:23support all of our patients across our communities. Yeah.
- 14:26And Aji is very humble in this regard, but I think to really push this forward
- 14:34we need a leader, physician leader likely, certainly somebody who is well versed in all of the complexities
- 14:44of precision medicine, genomics. So we're now starting to think about what that person would look like
- 14:50and how we would attract them into the northern New England arena.
- 14:56When you get those results back, how do we embed those within Epic so that they're available? Right.
- 15:02But at the same time, just like any other results that you have of individuals,
- 15:08how can we be respectful of the information protected for the individuals, their family and stuff?
- 15:15So, I think there's many levers that we're pulling, both the project,
- 15:21people, and then also technology. Yeah, yeah.
- 15:25Aji, I want to go back to communication strategies, and you talked a little
- 15:30bit about the outreach to patients will be done through MyChart.
- 15:36There's probably a step either before or after that, not just for our patients,
- 15:40but even for our own care team members.
- 15:43How are we going to communicate and educate so that folks really understand
- 15:48what genomics and precision medicine is, but do it without jargon and making
- 15:54it super, super complex?
- 15:56We have, through our work with the education work group for precision medicine,
- 16:02identified six groups that we are going to target for specific education, as you were mentioning.
- 16:09Clearly, the first and most important group is our patients.
- 16:14Thereafter come our physicians, our learners, our research coordinators,
- 16:20our genetic counselors, and also, and importantly, our staff members in the clinics.
- 16:25So, the content of information doesn't have to be the same.
- 16:31It has to be strong enough so people feel comfortable.
- 16:35And we have, for our patients, already started working on three different sets
- 16:41of information to be shared.
- 16:44One is the consenting process that I was talking about.
- 16:47Another one is informational brochures. And finally, and most importantly,
- 16:53it's the online references, including videos.
- 16:57Videos that will show really that patient journey I was referring to earlier
- 17:01on from the time they get the consent to the time they get the result.
- 17:06So that is what we are doing for now. Great.
- 17:10Well, as we think about wrapping up the conversation, I'd love to hear from
- 17:15both of you about what does success look like in the next two years,
- 17:21both for our patients and our clinicians, and how are we going to measure it?
- 17:26Maybe two years is too fast. Maybe it's five years.
- 17:29Pick the timeline, but what will success look like, and how are we going to
- 17:33measure that and know that we're achieving that North Star that we were aiming
- 17:38for? Maybe I'll start, Aji. Definitely, please, please contribute.
- 17:43I think if we're looking back in two or four years and the pilot is either completed,
- 17:51certainly well underway….
- 17:54We have a clearly defined leader in place. And number three,
- 17:59that our physicians and APPs, whether they're in primary care or in any specialty,
- 18:05they've got a basic vernacular under their belt,
- 18:10and they have a level of comfort with some new gene test biomarker is coming
- 18:17onto the market that they don't power in the corner,
- 18:21but now they're embracing it and they are challenging all of us to say,
- 18:27how do we incorporate that into advancing world-class care for our patients?
- 18:33How about you, Aji? Yeah, I fully agree with that.
- 18:36That was a wonderful statement, much better than what I would have said,
- 18:40which is the predetermined outcomes measures that we have identified based on
- 18:46our strategic priorities at MaineHealth, looking at the community, patient impact,
- 18:51processes of people, and finally, the financial health of this program.
- 18:57And the positivity rate, for example, of testing,
- 19:01the engagement of our patients, the engagement of our clinicians,
- 19:04and also because we are an academic medical center,
- 19:08the engagement of our learners, our residents, our students,
- 19:11how much we can help support them to become the future of health, right?
- 19:18Because this, for now, is a pilot, and we are trying to make it clinical practice.
- 19:24But by the time they practice, this will become, this will be the standard of
- 19:28care. Absolutely. Absolutely. Well...
- 19:31I know it was just kind of a little bit of a teaser of what's to come,
- 19:36but thank you both for joining me today and talking about how we're thinking
- 19:40about genomics precision medicine,
- 19:43and many of our listeners are our own patients, and so good for them to know
- 19:51to be on the lookout for when those notices start coming through MyChart.
- 19:54We encourage everybody to participate because that'll just make it more meaningful
- 19:59for everyone. But thank you both for talking about this, really the future of
- 20:04how we're going to deliver care.
- 20:06Really appreciate it. Thank you. Thank you.
- 20:09Well, I hope that you found this episode informative and provides a deeper insight
- 20:13into one of our major areas of focus as we continue to enhance how we work together
- 20:18as MaineHealth to achieve our vision of working together so that our communities
- 20:23are the healthiest in America.
- 20:24If you have ideas for topics for
- 20:28future podcasts, please email those to workingtogether@mainhealth.org.
- 20:33Thank you and have a blessed day.